Liver transplantation (LT) improves daily function and ameliorates gut microbial composition. However, the effect of LT on microbial functionality, which can be related to overall patient benefit, is unclear and could affect the post-LT course. The aims were to determine the effect of LT on gut microbial functionality focusing on endotoxemia, bile acid (BA), ammonia metabolism, and lipidomics. We enrolled outpatient patients with cirrhosis on the LT list and followed them until 6 months after LT. Microbiota composition (Shannon diversity and individual taxa) and function analysis (serum endotoxin, urinary metabolomics and serum lipidomics, and stool BA profile) and cognitive tests were performed at both visits. We enrolled 40 patients (age, 56 6 7 years; mean Model for End-Stage Liver Disease score, 22.6). They received LT 6 6 3 months after enrollment and were re-evaluated 7 6 3 months after LT with a stable course. A significant improvement in cognition with increase in microbial diversity, increase in autochthonous and decrease in potentially pathogenic taxa, and reduced endotoxemia were seen after LT compared with baseline. Stool BAs increased significantly after LT, and there was evidence of greater bacterial action (higher secondary, oxo and iso-BAs) after LT although the levels of conjugated BAs remained similar. There was a reduced serum ammonia and corresponding rise in urinary phenylacetylglutamine after LT. There was an increase in urinary trimethylamine-N-oxide, which was correlated with specific changes in serum lipids related to cell membrane products. The ultimate post-LT lipidomic profile appeared beneficial compared with the profile before LT. In conclusion, LT improves gut microbiota diversity and dysbiosis, which is accompanied by favorable changes in gut microbial functionality corresponding to BAs, ammonia, endotoxemia, lipidomic, and metabolomic profiles.
Liver transplantation (LT) is a lifesaving procedure in end-stage liver disease, which is usually characterized by an uneventful post-LT recovery.
(1) However, a subset of patients has a postoperative course that is characterized by multiple infections that can impair the overall prognosis. There is evidence of unfavorable gut microbiota in end-stage liver disease or dysbiosis that is strongly related to negative outcomes in the pre-LT period. (2, 3) In addition to an unfavorable gut microbial composition, there is also evidence of impaired microbial functionality in patients with advanced cirrhosis. This impaired functionality is reflected by a lower conversion from primary to secondary bile acids (BAs), changes in ammonia metabolism, as well as changes in microbial-mammalian cometabolites such as trimethylamine-N-oxide (TMAO). (4, 5) Because secondary BAs can suppress pathogens, their reduction in advanced cirrhosis is worrisome. (6) TMAO is a microbialmammalian cometabolite that has been shown to link gut microbiota with atherogenesis and cardiovascular changes in the pretransplant setting. (4) Given the proatherogenic profile after LT, the role of TMAO in this setting needs to be investigated. In addition, patients with cirrhosis often have hepatic encephalopathy (HE), characterized by endotoxemia, inflammation, and hyperammonemia. (7) Hyperammonemia is likely due to gut microbial production exacerbated by liver dysfunction. (8) This can potentially improve after LT in most cases, but the role of microbiota function toward this is unclear.
Although studies following patients from the pre-to the post-LT period have shown an improvement in gut microbial dysbiosis, functional changes have not been studied in detail. (9, 10) The role of gut microbiota composition and functionality in the modulation of the post-LT course is important because probiotic therapy has been inconsistently shown to improve these outcomes. (11) We hypothesized that there would be a significant microbial functional change after LT compared with their pre-LT baseline, which could be beneficial to the patients.
Patients and Methods

Patients listed for deceased donor LT at Virginia Commonwealth University Medical Center and McGuire Veterans Affairs Medical Center between
June 2011 and August 2015 were enrolled. We included patients who were between 21 and 65 years old and who were able to provide consent and give samples. We excluded those who were listed as status 1, listed for living donor LT, were unwilling to consent or provide samples or had human immunodeficiency virus, and those who were lost to follow-up. The protocol was approved by the institutional review boards at both institutions.
After informed consent, patients underwent stool collection for gut microbiota and BA analysis. Model for End-Stage Liver Disease (MELD) score and venous ammonia were measured. A 24-hour dietary recall was performed in all patients, along with psychometric hepatic encephalopathy score (PHES) testing, (7) which was used to diagnose minimal hepatic encephalopathy (MHE). (12) Stool bacterial DNA was extracted for multitagged sequencing using published techniques, (2) whereas BAs were evaluated using LC/MS techniques. Urine and serum were also collected during the same sitting for nuclear magnetic resonance (NMR) metabolomics and lipidomics, respectively (details below and in the Supporting Information).
The included patients were followed until LT, death on the waiting list, or delisting. For those who underwent transplantation, the transplant and immunosuppression regimen details, posttransplant course including hospitalizations, rejection episodes, and duration of hospital stay were recorded. The posttransplant visit was performed after 6 months in those patients who were alive and willing, and had not undergone a second transplant. This point was chosen in the post-LT timeframe to avoid immediate and transient postoperative complications. (13) At 6 months, all procedures performed at the baseline visit were repeated.
SPECIALIZED TESTING AND ANALYSES
Stool microbiome was assayed using Multitag sequencing on an Ion Torrent Personal Genome Machine (PGM). (2) The microbiota relative abundance was analyzed using Wilcoxon paired tests, and Linear Discriminant Analysis Effect Size (LEFSe) was used to compare the pre-LT microbiota profiles to the post-LT profiles. (14, 15) Stool BA levels were analyzed using published liquid chromatography-mass spectrometry (LC/MS) methods. (16) Urine was collected the same day for metabolomics using NMR spectroscopy using published techniques. (17) Serum lipidomics was performed using established methods. (18) Detailed testing methods are in the Supporting Information. Correlations and changes before/after LT using multiple-testing correction were performed between TMAO and lipidomics fractions. We also performed analysis of metabolites, diversity, and the cognitive status before/after LT. Correlations between changes (delta, post-LT minus pre-LT values) in Shannon diversity, individual bacterial phyla, BA profile, and urinary metabolites were also performed using Pearson correlations.
Results
We enrolled 57 patients, of whom 5 died or were delisted prior to LT and 4 were not able to provide all samples. The remaining 48 underwent transplantation, of whom 40 were seen after LT. Of the remaining 8, 3 died within 1 month of LT, 1 required retransplantation due to primary nonfunction, and 4 were lost to follow-up.
The 40 patients ultimately that underwent collections at both visits had a mean age of 56 6 7 years and a mean MELD of 22.6 6 6.3. The majority (n 5 30) were Caucasian and were men (n 5 35). The leading etiology of cirrhosis was hepatitis C (n 5 17), hepatitis C and alcohol (n 5 8), followed by nonalcoholic steatohepatitis (NASH; n 5 6), and others (n 5 9). Eleven patients were on the list primarily for hepatocellular cancer. Per Virginia Commonwealth University (VCU) protocol, all patients had a detailed cardiovascular workup, including cardiac catheterization, showing minimal atherosclerotic disease before listing. Patients received LT 6 6 3 months after enrollment. In the interim, of the 40, 9 patients were hospitalized, 6 for infections (2 with C. difficile, 2 with urinary tract infections with Klebsiella and E. coli, and 2 with spontaneous bacterial peritonitis [SBP] without an organism isolated), and 3 for anasarca.
These patients were re-evaluated 7 6 3 months after LT for their second visit. The VCU immunosuppression protocol consists of steroids tapered over 1 month with perioperative mycophenolate mofetil. Tacrolimus, started at day 3, is targeted to maintain 8-12 ng/mL levels within the first 3 months and 5-10 ng/mL after that period. Regular tacrolimus trough levels were monitored throughout, and all patients were within the trough values that were recommended (10.5 6 5.6 ng/ mL average tacrolimus level prior to 6-month visit).
In the immediate post-LT period, there were infections seen in 10 patients (C. difficile in 5, biliary sepsis in 4, and surgical wound infection in 2; 1 person had both biliary sepsis and C. difficile). An additional 2 patients showed acute cellular rejection within 3 months after LT treated with steroids, 4 required biliary interventions, and 2 needed changing of the primary immunosuppression from tacrolimus to cyclosporine due to neurotoxicity.
At the time of repeat evaluation, dietary recall and PHES testing were performed again. At that time, none of the patients had recurrence of cirrhosis or had hepatitis C virus (HCV) eradicated. At the time of sample collection, there were no signs of active bacterial and fungal infection, and the last use of antibiotics other than the recommended trimethoprim-sulfomethoxazole was at least 3 months prior. All patients were on calcineurin immunosuppression (tacrolimus in 38 and cyclosporine in 2 patients) with mycophenolate without sirolimus use. Details are shown in Table 1 .
There was a higher systolic and diastolic blood pressure (DBP) and lower body mass index (BMI) after LT ( Table 2 ). This was accompanied by recovery of the liver function and improvement in the hemoglobin, white blood cell (WBC) count, and renal function. Blood glucose levels were similar before and after LT. The dietary pattern, including the ingestion of meat and eggs and the total caloric value remained similar before and after transplant. The relative proportion of protein intake was similar before and after LT (17% calories from protein before versus 21% after LT).
COGNITIVE CHANGES
There was a significant improvement in PHES score with a lowering of the proportion of MHE after LT ( Table 2) . NOTE: Data are given as n, unless otherwise noted.
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MICROBIAL COMPOSITION AND ENDOTOXEMIA
There was a significant increase in Shannon diversity indices and reduction in serum endotoxin after LT (Table 2) . We found a significant reduction in the relative abundance of potentially pathogenic genera belonging to Enterobacteriaceae (Escherichia, Shigella, Salmonella) with a significant increase in potentially beneficial, autochthonous genera belonging to Ruminococcaceae and Lachnospiraceae, on LEFSe (Table 3 ).
BA CHANGES
The fecal BA profile after LT was characterized by a significant increase in total BAs including primary BAs, specifically cholic acid (Table 4) . When the bacterial actions on BAs were analyzed, there were similar conjugated BAs after LT but significantly higher secondary, iso, and oxo BAs.
URINARY METABOLOMICS
As shown in Fig. 1 , there were differences in urinary NMR spectroscopy as a whole before and after LT, including a significant increase in TMAO (increased 2.4-fold; P 5 0.01) and in phenylacetylglutamine (PAG; increased 2.7-fold; P 5 0.02) after LT.
AMMONIA CHANGES
There was a significant reduction in venous ammonia (Table 2) and also an increase in urinary PAG, as mentioned above.
LIPIDOMICS
We found a significant change in serum lipidomics after LT, which was related to changes across several lipid classes, diacylglycerols (DGs), cholesterol esters (CE), lyso-phosphethonolamine (LysoPE)/phosphoethanolamine (PE), and sphingomyelin (SM; all changes P < 0.05 after multiple testing correction 
RELATIONSHIP BETWEEN COGNITION, MICROBIAL FUNCTION, AND COMPOSITION BEFORE AND AFTER LT
Correlations before LT were significant between PHES and PAG (r 5 0.5; P 5 0.04) and with relative abundance of Firmicutes (r 5 0.42; P 5 0.05). PAG was also correlated positively with TMAO (r 5 0.6; P 5 0.02) and negatively with Proteobacteria relative abundance (r 5 20.47; P 5 0.03). TMAO was associated positively with primary (r 5 0.7; P 5 0.008) and total BAs (r 5 0.6, P 5 0.03). When delta changes were compared, delta PHES was negatively correlated with delta Proteobacteria (r 5 20.54; P 5 0.04) and PAG (r 5 20.51; P 5 0.05) and positively with Firmicutes (r 5 0.6; P 5 0.01). In addition, delta PAG and delta TMAO were positively linked (r 5 0.6; P 5 0.02). Changes in total, primary, and secondary BA were negatively linked with Proteobacteria (all r 5 20.54; P 5 0.01) and positively with Firmicutes (all r 5 0.49; P 5 0.05). No significant correlations between Shannon diversity before and after or delta diversity were found with these metabolites or cognitive changes.
Discussion
Our results demonstrate that there is a beneficial change in the gut microbiota composition and functionality after successful LT. These changes are manifested by an improvement in microbiota diversity and beneficial autochthonous bacterial composition, as well as improvement in the fecal BA profile and serum lipidomics. Prior studies have shown that an improvement in the gut microbial composition after LT is linked to brain function improvement. (9, 19) We also found a beneficial impact on ammonia metabolism and resumption of methylamine synthesis.
These findings add to our current knowledge where there is a dramatic clinical improvement in clinical and quality-of-life parameters in most patients with cirrhosis after a successful LT. (9, 20) However, the post-LT stage is also complicated by the use of immunosuppressive regimens, which can potentially modulate posttransplant outcomes. (1) In addition, recurrence of the cirrhosis etiology and incomplete recovery from the NOTE: Data are given as mean 6 SD. *P < 0.05 before versus after transplant using paired t tests.
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sequelae from complications such as HE can also occur in these patients. (21) In addition to the improvement in liver function and systemic hemodynamics, our results demonstrate an improvement of the gut microbial diversity. This was accompanied by a higher relative abundance of beneficial, autochthonous bacteria and a suppression of potentially pathogenic gram-negative taxa after LT, even with the use of immunosuppression and trimethoprim-sulfomethoxazole. (22) Tacrolimus can decrease Firmicutes and increase Bacteroidetes, but we found the opposite trend after LT. (22) This highlights the importance of a functioning liver in the mediation of gut microbial improvement and also demonstrates that the gut microbial changes in cirrhosis are a potential result of liver insufficiency rather than an independent pathophysiological factor in disease causation. (23) Moreover, these changes were accompanied by a significant reduction in endotoxemia, which can potentiate the systemic inflammatory milieu seen in patients with cirrhosis. (24, 25) This is a functional correlate of the reduction in gram-negative taxa such as those belonging to Enterobacteriaceae. In addition, the potential improvements in the intestinal barrier due to increase in short-chain fatty acid producing Lachnospiraceae and Ruminococcaceae, reversal of portal hypertension, and improvement in the immune function could also contribute to the reduction in post-LT endotoxemia.
A major component of the gut-liver axis are BAs, which are pleiotropic signaling molecules. (26) Primary BAs (cholic and chenodeoxycholic acid) are synthesized from cholesterol in the liver and released into the duodenum conjugated with glycine or taurine. Bacterial modification in the intestine results in deconjugation (removal of the glycine/taurine) followed by 7a dehydroxylation, forming secondary BAs (deoxycholic and lithocholic acid). (27) Both secondary and primary BAs can further undergo a reversible transformation into oxo-BAs in the colonic bacteria. It makes them more hydrophilic and less toxic. Another bacterial transformation is the epimerization of BAs to form the nontoxic iso-BAs. Although most bacterial taxa are able to deconjugate BAs and form oxo-BAs, only selected microbes are able to perform 7a dehydroxylation and conversion to iso-BAs. (26) In patients with cirrhosis, due to liver disease and intrahepatic/extrahepatic cholestasis, there is a low BA production and secretion into the intestine.
(5) Furthermore, there is a reduction in secondary BAs, likely due to lower relative abundance of autochthonous beneficial bacteria that mediate their formation. (28) Therefore, the increase in total BAs with significant increase in secondary, iso-and oxo-BAs is a reflection of the increase in Firmicutes and reduction in Proteobacteria after LT, which indicates an improvement of the intestinal milieu. This could afford greater protection against nosocomial bacteria such as C. difficile, which are inhibited to a greater degree by secondary but not by primary BA moieties. (6) Another aspect of gut microbial function is the conversion of dietary amino acids and proteins into ammonia, which can be complicit in the development of HE. (7) In healthy subjects, in addition to fixation of the ammonia into the urea cycle by the liver, there is a urinary excretion in the form of PAG. After LT, there was a reduction in venous ammonia that was accompanied by higher urinary PAG, indicating again an improvement in ammonia metabolism. Moreover, as previously reported, this was associated with Proteobacteria and Firmicutes relative abundance changes (9) and also to urinary PAG level changes after LT.
While improvement in BAs, microbial diversity, and endotoxemia point toward an overall improvement, there was also a significant increase in urinary TMAO. The mammalian microbial cometabolite is produced through bacterial action on dietary carnitine and choline, and subsequent oxidation in the liver with flavin mono-oxygenases. (4) TMAO is associated with negative cardiovascular outcomes and is associated with atherogenesis in noncirrhotic individuals. (29) Moreover, in patients without cirrhosis, TMAO can potentially interfere with hepatic BA synthesis. (29) Given the significant increase in the fecal BA content despite this increase in TMAO, it is unlikely that there was a meaningful inhibition of hepatic BA synthesis in the newly transplanted livers. In patients with cirrhosis, cognitive dysfunction is linked with TMAO levels. (30, 31) Because the formation of TMAO requires a functioning microbiota and liver, the return to normal function after LT of both of these organ systems make it difficult to separate the relative contribution of microbiota compared with the liver in the development of higher post-LT TMAO levels. Specifically bacterial taxa that are responsible for the conversion of primary to secondary BAs can also convert dietary choline into trimethylamine (TMA), ie, Clostridium cluster XIV. (23, 32, 33) On the other hand, there is evidence that members of Enterobacteriaceae possess the genes to convert dietary carnitine into TMA. (32, 33) It is likely that the enhanced liver function was largely responsible for this increase given that dietary patterns, including red meat and egg intake, remained similar before and after LT and the bacterial profile demonstrated a mixed picture with respect to TMA converting taxa with a higher Clostridium cluster XIV and lower Enterobacteriaceae after LT.
To better define the relationship of TMAO and potential atherogenesis, serum lipidomic changes were studied. Lipid profiles after LT showed a trend toward normalization with the profile changing from shorterchain fatty acids and markers of cell membrane damage before LT to that of longer-chain fatty acids and intact cell membrane markers after LT. Specific changes in the lipidomics analysis reveal several interesting results. The choline degradation pathway with TMAO generation represents a unique additional nutritional contribution to the pathogenesis of cardiovascular disease that involves phosphatidylcholine and choline metabolism, an obligate role for the intestinal microbial community, and regulation of surface expression levels of macrophage scavenger receptors known to participate in the atherosclerotic process. (34) Choline is a constituent of phosphatidylcholine, and it is essential for the structural integrity of cell membranes, acetylcholine synthesis, cell-membrane signaling, and methyl-group metabolism. Changes in DG after LT are relevant because fish oils, those rich in omega 3 fatty acids (docosahexaenoic acid [DHA] and eicosapentanoic acid [EPA]) in particular, help to prevent the progression of atherosclerosis by inhibiting the development of plaques and blood clots at lesion sites. (35) Dietary DAG might be useful for the regression of atherosclerosis compared with TAG, which has a similar fatty acid composition, suggesting that the effects of DAG are related to the acylglycerol structure. (36) SM change with LT is important because, in addition to being a major lipid component of plasma and cell membranes, it is an independent risk factor for coronary artery disease. (37) Oxidized cholesterol (oxysterols) enhances the production of SM, a phospholipid found in the cellular membranes of the coronary artery. This increases the SM content in the cell membrane, which in turn increases the risk of arterial calcification. (37) The redistribution of CEs, triglycerides, and, to a lesser extent, phospholipids in plasma could be achieved by glycoprotein which is secreted by the liver, and circulates in plasma, which could also modulate the risk of atherosclerosis. (38) (39) (40) Ultimately, beneficial lipidomic markers were significantly correlated with TMAO increase after LT. At this stage after LT, it is unlikely to see de novo cardiovascular consequences, and the selection of our patients ensured that those with an eventful postoperative course had stabilized months before inclusion. Therefore, the increase in TMAO at this early post-LT stage is likely a manifestation of a return to relative normalcy of the liver, given that it was positively linked with other beneficial changes such as increase in urinary PAG and decrease in gut Proteobacteria relative abundance. These changes are even more relevant because all pre-LT patients are cleared from a cardiovascular perspective before listing. Given that most post-LT cardiovascular disease occurs several years later, further longitudinal follow-up is required to determine if this TMAO increase persists and is related to atherogenic events further along the post-LT course.
We only included stable patients at 6 months after transplant and excluded those with recent rejection and infectious events. This implies that these events could not be prognosticated by the microbial functional changes. However, our aim was to determine the reversibility of microbial functional changes after LT and needed to avoid confounding factors. The study is limited by the relatively small number of patients with NASH, who could indeed have a worse post-LT atherogenic course. In addition, none of our HCV patients underwent eradication before or after LT given the timeframe of recruitment, which could potentially change these results given the effect of HCV on lipidomics. (41) Although individual taxa were linked as expected to metabolites and outcomes, there was no significant relationship with Shannon diversity. This could be due to the relative narrow skewed diversity before LT and also reflects that diversity is only 1 aspect of the complex microbial analysis. We also performed the sample analysis at a time point beyond any bacterial infections such as C. difficile. Therefore, these data cannot be leveraged to analyze that risk. We do not have healthy control data for comparison but given the significant comorbid conditions, the patients serving as their own control was considered appropriate. However, the microbiota composition, BA profiles, endotoxin levels, and lipodomic changes approximate the healthy population values. (2, 5, 9, 42) We conclude that after successful LT there is a significantly beneficial change in gut microbial function that spans endotoxin synthesis, ammonia, BA modulation, and methylamine metabolism. Cumulatively, these changes indicate a return to normal gut microbial composition and function in diverse aspects within 6 months of a successful LT and underline the central role of the liver in determining the gut microbial function.
